Cargando…
Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes
Carotid bodies (CBs) are peripheral chemoreceptors that sense changes in blood O(2), CO(2), and pH levels. Apart from ventilatory control, these organs are deeply involved in the homeostatic regulation of carbohydrates and lipid metabolism and inflammation. It has been described that CB dysfunction...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432672/ https://www.ncbi.nlm.nih.gov/pubmed/32756352 http://dx.doi.org/10.3390/ijms21155545 |
_version_ | 1783571848801288192 |
---|---|
author | Sacramento, Joana F. Andrzejewski, Kryspin Melo, Bernardete F. Ribeiro, Maria J. Obeso, Ana Conde, Silvia V. |
author_facet | Sacramento, Joana F. Andrzejewski, Kryspin Melo, Bernardete F. Ribeiro, Maria J. Obeso, Ana Conde, Silvia V. |
author_sort | Sacramento, Joana F. |
collection | PubMed |
description | Carotid bodies (CBs) are peripheral chemoreceptors that sense changes in blood O(2), CO(2), and pH levels. Apart from ventilatory control, these organs are deeply involved in the homeostatic regulation of carbohydrates and lipid metabolism and inflammation. It has been described that CB dysfunction is involved in the genesis of metabolic diseases and that CB overactivation is present in animal models of metabolic disease and in prediabetes patients. Additionally, resection of the CB-sensitive nerve, the carotid sinus nerve (CSN), or CB ablation in animals prevents and reverses diet-induced insulin resistance and glucose intolerance as well as sympathoadrenal overactivity, meaning that the beneficial effects of decreasing CB activity on glucose homeostasis are modulated by target-related efferent sympathetic nerves, through a reflex initiated in the CBs. In agreement with our pre-clinical data, hyperbaric oxygen therapy, which reduces CB activity, improves glucose homeostasis in type 2 diabetes patients. Insulin, leptin, and pro-inflammatory cytokines activate the CB. In this manuscript, we review in a concise manner the putative pathways linking CB chemoreceptor deregulation with the pathogenesis of metabolic diseases and discuss and present new data that highlight the roles of hyperinsulinemia, hyperleptinemia, and chronic inflammation as major factors contributing to CB dysfunction in metabolic disorders. |
format | Online Article Text |
id | pubmed-7432672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74326722020-08-27 Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes Sacramento, Joana F. Andrzejewski, Kryspin Melo, Bernardete F. Ribeiro, Maria J. Obeso, Ana Conde, Silvia V. Int J Mol Sci Review Carotid bodies (CBs) are peripheral chemoreceptors that sense changes in blood O(2), CO(2), and pH levels. Apart from ventilatory control, these organs are deeply involved in the homeostatic regulation of carbohydrates and lipid metabolism and inflammation. It has been described that CB dysfunction is involved in the genesis of metabolic diseases and that CB overactivation is present in animal models of metabolic disease and in prediabetes patients. Additionally, resection of the CB-sensitive nerve, the carotid sinus nerve (CSN), or CB ablation in animals prevents and reverses diet-induced insulin resistance and glucose intolerance as well as sympathoadrenal overactivity, meaning that the beneficial effects of decreasing CB activity on glucose homeostasis are modulated by target-related efferent sympathetic nerves, through a reflex initiated in the CBs. In agreement with our pre-clinical data, hyperbaric oxygen therapy, which reduces CB activity, improves glucose homeostasis in type 2 diabetes patients. Insulin, leptin, and pro-inflammatory cytokines activate the CB. In this manuscript, we review in a concise manner the putative pathways linking CB chemoreceptor deregulation with the pathogenesis of metabolic diseases and discuss and present new data that highlight the roles of hyperinsulinemia, hyperleptinemia, and chronic inflammation as major factors contributing to CB dysfunction in metabolic disorders. MDPI 2020-08-03 /pmc/articles/PMC7432672/ /pubmed/32756352 http://dx.doi.org/10.3390/ijms21155545 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sacramento, Joana F. Andrzejewski, Kryspin Melo, Bernardete F. Ribeiro, Maria J. Obeso, Ana Conde, Silvia V. Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes |
title | Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes |
title_full | Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes |
title_fullStr | Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes |
title_full_unstemmed | Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes |
title_short | Exploring the Mediators that Promote Carotid Body Dysfunction in Type 2 Diabetes and Obesity Related Syndromes |
title_sort | exploring the mediators that promote carotid body dysfunction in type 2 diabetes and obesity related syndromes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432672/ https://www.ncbi.nlm.nih.gov/pubmed/32756352 http://dx.doi.org/10.3390/ijms21155545 |
work_keys_str_mv | AT sacramentojoanaf exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes AT andrzejewskikryspin exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes AT melobernardetef exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes AT ribeiromariaj exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes AT obesoana exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes AT condesilviav exploringthemediatorsthatpromotecarotidbodydysfunctionintype2diabetesandobesityrelatedsyndromes |